Spiro Medical Treats First Asthma Patient With Neuromodulation in IDE Feasibility Study

Trial StartPositive

AI Analysis

Summary

Spiro Medical announced treatment of its first patient with severe, uncontrolled asthma using a neuromodulation-based device in an IDE feasibility study. This represents an early-stage clinical milestone for the company's investigational respiratory therapy.

Clinical Trial Data

Patients

Outcome Details

First patient treated in IDE feasibility study

Importance:3/10

Sentiment:

0.50

neuromodulationasthmamedical deviceIDE feasibility studychronic respiratory disease

Related Companies

$MDCE $TRAX

Read the original article

Published by PR Newswire Clinical Trials on October 12, 2026 10:00 AM

Read Original